Rezultati - Chandiwana, David

Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom od Suri, Gaurav, Chandiwana, David, Lee, Adam, Mistry, Rohit

Polni tekst Polni tekst Polni tekst

Patient experiences with patient-reported outcome measures in metastatic breast cancer trials: qualitative interviews od Romano, Carla, Harris, Nimanee, Gnanasakthy, Ari, D’Alessio, Denise, Chandiwana, David

Polni tekst Polni tekst Polni tekst

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2− metastatic breast cancer od Forsythe, Anna, Chandiwana, David, Barth, Janina, Thabane, Marroon, Baeck, Johan, Tremblay, Gabriel

Polni tekst Polni tekst Polni tekst

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer od Tremblay, Gabriel, Chandiwana, David, Dolph, Mike, Hearnden, Jaclyn, Forsythe, Anna, Monaco, Mauricio

Polni tekst Polni tekst Polni tekst

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom od Amdahl, Jordan, Diaz, Jose, Sharma, Arati, Park, Jinhee, Chandiwana, David, Delea, Thomas E.

Polni tekst Polni tekst Polni tekst

Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil od Buehler, Anna Maria, Dionne, Pierre-Alexandre, Chandiwana, David, Pathak, Purnima, Igho-Osagie, Ebuwa

Polni tekst

Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer? od Forsythe, Anna, Chandiwana, David, Barth, Janina, Thabane, Marroon, Baeck, Johan, Shor, Anastasiya, Tremblay, Gabriel

Polni tekst Polni tekst Polni tekst

Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribocic... od Verma, Sunil, O’Shaughnessy, Joyce, Burris, Howard A., Campone, Mario, Alba, Emilio, Chandiwana, David, Dalal, Anand A., Sutradhar, Santosh, Monaco, Mauricio, Janni, Wolfgang

Polni tekst Polni tekst Polni tekst

Effectiveness of Alpelisib + Fulvestrant Compared with Real‐World Standard Treatment Among Patients with HR+, HER2–, PIK3CA‐Mutated Breast Cancer od Turner, Stuart, Chia, Stephen, Kanakamedala, Hemanth, Hsu, Wei‐Chun, Park, Jinhee, Chandiwana, David, Ridolfi, Antonia, Yu, Chu‐Ling, Zarate, Juan Pablo, Rugo, Hope S.

Polni tekst Polni tekst Polni tekst

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer od Fasching, Peter A, Delea, Thomas E, Lu, Yen-Shen, De Boer, Richard, Hurvitz, Sara A, Moynahan, Aaron, Chandiwana, David, Lanoue, Brad, Hu, Huilin, Thuerigen, Astrid, O’Shaughnessy, Joyce

Polni tekst Polni tekst Polni tekst

Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results f... od Harbeck, Nadia, Franke, Fabio, Villanueva-Vazquez, Rafael, Lu, Yen-Shen, Tripathy, Debu, Chow, Louis, Babu, Govind K, Im, Young-Hyuck, Chandiwana, David, Gaur, Anil, Lanoue, Brad, Rodriguez-Lorenc, Karen, Bardia, Aditya

Polni tekst Polni tekst Polni tekst

Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2− advanced breast cancer od Tripathy, Debu, Curteis, Tristan, Hurvitz, Sara, Yardley, Denise, Franke, Fabio, Babu, K. Govind, Wheatley-Price, Paul, Im, Young-Hyuck, Pencheva, Radost, Eddowes, Lucy A., Dionne, Pierre-Alexandre, Chandiwana, David, Pathak, Purnima, Lanoue, Brad, Harbeck, Nadia

Polni tekst Polni tekst Polni tekst

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study od Fasching, Peter A., Beck, J. Thaddeus, Chan, Arlene, De Laurentiis, Michele, Esteva, Francisco J., Jerusalem, Guy, Neven, Patrick, Pivot, Xavier, Bianchi, Giulia V., Martin, Miguel, Chandiwana, David, Lanoue, Brad, Ridolfi, Antonia, Wang, Yingbo, Rodriguez Lorenc, Karen, Nusch, Arnd

Polni tekst Polni tekst Polni tekst